OncoMatch/Clinical Trials/NCT07239323
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Is NCT07239323 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Invivo CAR-T for b-acute lymphoblastic leukemia.
Treatment: Invivo CAR-T — This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration
Cannot have received: targeted therapy
Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration
Cannot have received: immunotherapy
Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration
Cannot have received: radiation therapy
Exception: if the radiotherapy target area covers ≤ 5% of bone marrow reserve, the time limit for radiotherapy completion is not restricted
Received radiotherapy within 4 weeks before administration
Cannot have received: allogeneic hematopoietic stem cell transplantation
Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration
Cannot have received: autologous hematopoietic stem cell transplantation
Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration
Cannot have received: VSVG pseudotyped virus therapy
Received treatment related to vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus in the past
Lab requirements
Blood counts
Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening, rhEPO allowed); ANC ≥ 600/μL (no G-CSF within 1 week, no peg-G-CSF within 2 weeks before screening); Platelet count ≥ 50,000/μL; Lymphocyte count ≥ 500/μL
Kidney function
creatinine clearance rate (CrCl) ≥ 45 mL/min (Cockcroft-Gault formula)
Liver function
ALT, AST ≤ 3.0 × ULN; TBIL ≤ 2.0 × ULN (except for congenital hyperbilirubinemia such as Gilbert's syndrome, direct bilirubin can be relaxed to ≤ 1.5 × ULN)
Cardiac function
LVEF ≥ 40% (echocardiography or MUGA); No clinically significant pericardial effusion; No clinically significant ECG abnormalities
Blood routine test results during the screening period meet the following criteria: Hemoglobin ≥ 6 g/dL... ANC ≥ 600/μL... Platelet count ≥ 50,000/μL; Lymphocyte count ≥ 500/μL; Normal renal function: CrCl ≥ 45 mL/min; Liver function: ALT, AST ≤ 3.0 × ULN; TBIL ≤ 2.0 × ULN... Cardiac function: LVEF ≥ 40%... No clinically significant pericardial effusion; No clinically significant ECG abnormalities
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify